Patent ID: 7323346

Claim:
A method of determining whether a pregnant human subject has, or is predisposed to having, preeclampsia, the method comprising: obtaining a urine sample from the pregnant human subject at between about 16 to 18 or 18 to 24 weeks of gestation; measuring levels of at least two specific proteins selected from the group consisting of monocyte chemoattractant protein-1 (MCP-1), soluble TNF receptor I (sTNFR-I), soluble TNF receptor II (sTNFR-II), interleukin (IL)-1α, IL-1β, IL-4, IL-6, and IL-8, in the subject urine sample; generating a subject profile comprising at least two values, each value representing a level of one of said specific proteins; comparing the subject profile with a reference profile, wherein the reference profile comprises two or more values, each value representing a reference level one of said specific proteins; and determining whether the pregnant human subject has, or is predisposed to having, preeclampsia based on the comparison of the subject profile with the reference profile.